Science
CME credits: 0.25 Valid until: 15-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/raasi-therapy-diabetes-and-hyperkalemia-halting-therapy-not-only-option/12714/ In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.